We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Maintains Draft Rule Will Help Ensure Integrity of Submitted Data
FDA Maintains Draft Rule Will Help Ensure Integrity of Submitted Data
November 4, 2010
Why does the FDA want to impose another regulation on industry, when existing rules and sanctions would, in theory at least, deal with anyone attempting to fabricate clinical trial data? One big reason: The FDA believes there is strong support for initiating the rule. In the preamble, the FDA maintains that the proposed rule is designed to ensure the integrity of data submitted to the agency. In short, reliance on fabricated data could lead to: